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doi:10.1Objective: Lung cancer is the leading cause of cancer death in North America. Low-dose computed tomography
screening can reduce lung cancer–specific mortality by 20%.
Method: The American Association for Thoracic Surgery created a multispecialty task force to create screening
guidelines for groups at high risk of developing lung cancer and survivors of previous lung cancer.
Results: The American Association for Thoracic Surgery guidelines call for annual lung cancer screening with
low-dose computed tomography screening for North Americans from age 55 to 79 years with a 30 pack-year
history of smoking. Long-term lung cancer survivors should have annual low-dose computed tomography to de-
tect second primary lung cancer until the age of 79 years. Annual low-dose computed tomography lung cancer
screening should be offered starting at age 50 years with a 20 pack-year history if there is an additional cumu-
lative risk of developing lung cancer of 5% or greater over the following 5 years. Lung cancer screening requires
participation by a subspecialty-qualified team. The American Association for Thoracic Surgery will continue
engagement with other specialty societies to refine future screening guidelines.
Conclusions: The American Association for Thoracic Surgery provides specific guidelines for lung cancer
screening in North America. (J Thorac Cardiovasc Surg 2012;144:33-8)Lung cancer remains the most common cause of cancer
death in the United States and Canada. This year there
will be more lung cancer deaths alone than the combined
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The Journal of Thoracic and Cscreening programs have identified early cases of the other
3 cancers, but until recently lung cancer has lacked an effec-
tive screening tool.
Changes in disease demographics have witnessed a dou-
bling of lung cancer incidence and a decline in tuberculosis
over the past 30 years. Minimally invasive techniques have
dramatically improved the safety and expected recovery of
surgical resections. Most important, the publication of the
National Lung Screening Trial (NLST) has established the
ability of low-dose computed tomography (LDCT) scans
to decrease lung cancer–specific mortality by 20% in
a screened high-risk population.1
As a result of the International Association for the Study
of Lung Cancer (IASLC) Screening Workshop 2011, the
IASLC created a Strategic Screening Advisory Committee
to engage stakeholder professional societies in lung cancer
computed tomography (CT) screening implementation
across the globe. The charge was to deliver guidelines for
radiologic screening, clinical workup for indeterminate
nodules, pathology reporting of nodules, and recommenda-
tions for surgical and therapeutic interventions for suspi-
cious nodules. In addition, societies were charged to
create guidelines and recommendations for identification
of high-risk individuals for lung cancer CT screening and
integration of smoking cessation. The IASLC framed these
goals for the integration of lung cancer screening guidelines
into the existing healthcare structure of each nation. Theardiovascular Surgery c Volume 144, Number 1 33
Abbreviations and Acronyms
AATS ¼ American Association for Thoracic
Surgery
CT ¼ computed tomography
CXR ¼ chest x-ray
FEV1 ¼ forced expiratory volume in 1 second
IASLC ¼ International Association for the Study
of Lung Cancer
LDCT ¼ low-dose computed tomography
NLST ¼ National Lung Screening Trial
Clinical Guidelines Jaklitsch et alAmerican Association for Thoracic Surgery (AATS) has
begun this process for the United States and Canada.2MATERIALS AND METHODS
The AATS convened a lung cancer screening and surveillance task force
to examine the evidence in favor of lung cancer screening. The specific goal
of this panel was to provide guidelines to health care practitioners who care
for high-risk populations, including smokers and nonsmokers, with addi-
tional risk factors. An additional specific mandate was to develop guide-
lines for screening lung cancer survivors. This multidisciplinary panel
included representatives from thoracic surgery, medical oncology, pulmo-
nology, pathology, and radiology, with members selected on the basis of
demonstrated expertise in identifying risks and benefits of screening lung
cancer using LDCT. Although the following recommendations of this
task force may be applicable to many parts of the world, they are specifi-
cally intended to guide screening within the United States and Canada.
This recommendation is based on the high incidence of lung cancer within
these 2 highly developed nations, a rate that exceeds other regions of North
America. Specifically, the age-standardized incidence rate is 42.13 per
100,000 people of all ages and both sexes in the United States (third largest
in the world) and 35.88 per 100,000 in Canada (ninth largest in the world).3
Other areas of Latin America and the Caribbean have age-standardized
incidence rates less than 10 per 100,000 people.
In broad overview, our task force guidelines build on the work of the
NLST,1 as recommended by the IASLC Computed Tomography Screening
Workshop of 2011 report.2 Our recommendations further expand the re-
cently published National Comprehensive Cancer Network Guidelines
Version 1.2012 for Lung Cancer Screening.4 We do not limit screening
to the highest risk group of smokers recruited to the NLST trial, but recom-
mend screening for a larger population by both age and by broadening the
risk categories. We support the development of databases for refinement of
evidence-based guidelines. We believe LDCT provides an opportunity for
a ‘‘teachable moment’’ for tobacco cessation. Furthermore, we identify fu-
ture areas of research that are likely to influence the screening of lung can-
cer in the near future, such as the incorporation of biomarker data into
screening decisions.RESULTS
The American Association for Thoracic Surgery
Guidelines for Lung Cancer Screening in North
America
Our present culmination of knowledge leads this panel to
offer tiered recommendations in regard to 3 screening popu-
lations (Figures 1-5). Tier 1 includes those subjects at highest
risk for whom there is level 1 evidence5 to recommend
screening (ie, randomized prospective clinical trial data).34 The Journal of Thoracic and Cardiovascular SurgeTier 2 includes those subjects with level 2 evidence (ie,
data from case-control or nonrandomized trials) or level 3
evidence (ie, our consensus opinion) and sufficient evidence
to recommend screening for individuals within this group.
Tier 1 Guideline for Highest Risk Population
Annual lung cancer screening should begin at age 55
years for smokers and former smokers with a 30 pack-
year history of smoking. Annual screening may continue
to age 79 years (Figure 1). LDCT is the screening technol-
ogy to be used. CXR alone should not be used as a screening
tool. Individuals for whom adequate treatment cannot be of-
fered because of comorbidity or functional status, regard-
less of age, should not undergo screening.
This recommendation is based on the prospective ran-
domized NLST.1 According to the US Preventive Services
Task Force, this achieves level 1 evidence (ie, data from
a well-designed randomized control trial).5 The entry crite-
ria for the NLST trial included ages 55 to 74 years, 30
pack-years of tobacco exposure, and, if the subject had
quit smoking, smoking within the previous 15 years. We
have dropped the third entry criteria, believing the primary
risk generators are age and tobacco exposure, thus simplify-
ing the recommendation.
The NLST included 3 annual screens and identified
a 20% reduction in lung cancer–specific mortality within
the first 3 years of screening. The cancer risk does not end
after 3 years, however, and there is no scientific evidence
to suggest that screening should be stopped after the initial
3 annual low-dose scans.
We recognize the constraint of the trial design of the
NLST protocol whereby asymptomatic individuals without
a previous cancer diagnosis (excluding skin cancer) at high
risk because of smoking exposure (at least 30 pack-years)
and agewere selected for screening over 3 years. These con-
straints in the study population that were necessary to com-
plete the trial that established the efficacy of LDCT to
reduce lung cancer mortality would exclude many Ameri-
cans who would benefit from a lung cancer screening pro-
gram. These constraints need to be examined as we move
from a successful clinical trial to screening guidelines.
We recommend that annual LDCT screening be per-
formed each year from age 55 to 79 years, and not just 3
screening scans in the lifetime of the patient. The risk of
lung cancer does not decrease in subsequent years accord-
ing to the NLST data. In the NLST, participants were
screened yearly with LDCT or chest x-ray (CXR) for 3
years. After the period of active screening, they were fol-
lowed but not screened for another 4 years. At the end of
3 years, there were 649 cancers detected in the LDCT arm
compared with 279 cancers in the CXR arm. The number
of lung cancers increased each year to a total of 1060 in
the LDCT arm and 941 in the CXR arm at the end of the
study. The original NLST report (Figure 6) shows anry c July 2012
FIGURE 1. AATS lung cancer screening guidelines category 1 for highest risk. CT, Computed tomography; LDCT, low-dose computed tomography.
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with the CXR arm for the first 3 years (active screening pe-
riod), but does not demonstrate any obvious change in the
yearly rates of lung cancer on either arm for the last 4 years
of the study (observation period during which time there
was no screening LDCT). Furthermore, 63% of the lung
cancers (400/635) were diagnosed as stage I on the LDCT
arm during the first 3 years of active screening, and 21%
(130/635) were diagnosed in stage III B/IV. At the end of
the study in the LDCT arm (3 years active screening plus
4 years of follow-up only), the percentage diagnosed in
stage I had decreased to 50% (520/1040), and the stage
III B/IV cases had increased to 33% (348/1040). It is likely
that if active LDCT screening had been maintained for the 7
years of the study that the percentage of diagnoses in stage I
would have been higher and the percentage diagnosed in
stage III B/IV would have been lower than those reported
in the final NLST results. CT screening for 7 years is likely
to have translated into a substantially greater mortality re-
duction than the 20% reported in the final NLST results.
We recommend continued screening to age 79 years for
the following reasons:
1. The peak incidence of lung cancer is age 70 years in the
United States.6
2. The average life expectancy is currently 78.6 years; thus,
approximately half of all Americans are expected to live
until approximately 80 to 89 years of age.7
3. Age alone is a risk factor for lung cancer. Age-specific
incidence of lung cancer in American men increases in
a linear fashion with age, with rates of 336 per
100,000 aged 66 to 70 years, 490 per 100,000 aged 71FIGURE 2. AATS lung cancer screening guidelines for combined risk or lun
tomography; COPD, chronic obstructive pulmonary disease; FEV1, forced exp
The Journal of Thoracic and Cto 75 years, and 517 per 100,000 aged more than 75
years. For women, the peak incidence is 350 per
100,000 from ages 71 to 75 years, and then decreases
to 307 per 100,000 for women aged more than 75 years,
still higher than the incidence of 248 per 100,000 for
women aged 66 to 70 years.8
4. The average life expectancy remains greater than 9 addi-
tional years for all Americans up to age 79 years.
Thus, if nothing else is different, the risk of developing
lung cancer is slightly higher each year than the year before
because of aging. For this reason, we believe annual screens
should continue yearly up to the age of 79 years. Beyond the
age of 79 years, it is unclear if there would be the same
screening advantage in detecting an early-stage lung cancer
because of competing causes of mortality. Life-table analy-
sis suggests the probability of living 7 additional years de-
creases to less than 50% in the early ninth decade of life.9
However, patients aged more than 79 years with preserved
functional status may be a population with screening bene-
fit, although inadequate data are currently available.Tier 2 Guidelines for Lung Cancer Survivors and
Patients With Combined Risk
Annual lung cancer LDCTscreening should be performed
in patients who have been treated for a primary broncho-
genic carcinoma and have completed 4 years of radiographic
surveillance without evidence for recurrence (level 3 evi-
dence) or patients aged 50 to 79 years with a 20 pack-year
smoking history and other factors that produce a cumulative
risk of developing lung cancer that is 5% or more over theg cancer survivor. CT, Computed tomography; LDCT, low-dose computed
iratory volume in 1 second.
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FIGURE 3. AATS lung cancer screening guidelines for solid nodules on low-dose computed tomography (LDCT). PET/CT, Positron emission tomography/
computed tomography.
Clinical Guidelines Jaklitsch et alfollowing 5 years (level 2 evidence, Figure 2). This is similar
to the NCCN guidelines,4 although we recommend contin-
ued annual screening beyond 3 years and up to age 79 years
for the reasons stated. The data are consistent with US Pre-
ventive Services Task Force level 2 evidence (ie, data from
nonrandomized trials). This recommendation achieved
unanimous approval by the AATS Task Force.
High-resolution CT scans should be obtained for 4 years
after surgical resection of stages 1A to IIIA NSCLC, fol-
lowed by annual LDCT screening scan for a second primary
lung cancer starting in the fifth year. Surveillance by LDCT
should continue for the rest of the patient’s life as long as the
patient has functional status and pulmonary reserve needed
for treatment of a new lung cancer. These patients are well
served by the preservation of preoperative CT scans for
comparison of small nodules over longer time periods.
Baseline clinical CT scanning is recommended at 6 months
after surgical resection. Because of the peak incidence of re-
currence between 2 and 3 years, surveillance should be per-
formed at least every 6 months during this period.
Thosewho have had lung cancer are at the highest risk for
developing the disease because of recurrence and secondFIGURE 4. AATS lung cancer screening guidelines for grou
36 The Journal of Thoracic and Cardiovascular Surgeprimary. A history of lung cancer (and often other primary
cancers) removes the individual from the group analyzed by
screening studies. In fact, this group has been specifically
excluded from the randomized trials to date because of trial
design. Yet, such individuals need surveillance with con-
tinuing 3% risk of lung cancer diagnosis each year. There
are currently more than 400,000 long-term lung cancer
survivors in the United States.
The other risk factors accepted by the AATS Lung Can-
cer Screening Committee as contributing to the cumulative
risk of developing lung cancer include (1) chronic obstruc-
tive pulmonary disease with forced expiratory volume in 1
second (FEV1) of 70% or less than predicted, (2) environ-
mental and occupational exposures, (3) any prior cancer
or thoracic radiation, and (4) a genetic or family history.
The Liverpool Lung Project has combined case-control
data with regional incidence rates to develop amodel to pro-
ject individual 5-year absolute risks of developing lung can-
cer.10 Predictive variables of lung cancer risk within this
model include age, gender, smoking duration, prior diagno-
sis of pneumonia, occupational exposure to asbestos, prior
diagnosis of malignant tumor, and family history of lungnd-glass nodule. LDCT, Low-dose computed tomography.
ry c July 2012
FIGURE 5. AATS lung cancer screening guidelines of new nodule on screening scan on low-dose computed tomography (LDCT). PET/CT, Positron emis-
sion tomography/computed tomography.
Jaklitsch et al Clinical Guidelinescancer. There is a nonlinear relationship between decrease
in FEV1 and cancer risk. However, randomized Italian trials
identified an FEV1 of less than 70% predicted to be a thresh-
old to identify a high-risk lung cancer population among
smokers with a 20 pack-year smoking history.11
Exposure to asbestos is known to be synergistic with to-
bacco smoking. Another environmental factor associated
with a synergistic effect on lung cancer risk includes silico-
sis.12 As environmental medicine expands, other exposures
will likely be identified that increase the risk of broncho-
genic malignancy. In the face of these types of environmen-
tal or occupational exposures, CT screening should beFIGURE 6. Annual screening should produce greater than 20% reduction
in lung cancer–specific mortality. There is an increase in detected cancers
in the LDCTarm during the active screening period, but not after the start of
the observation period (arrow). Reprinted with permission.1 Copyright the
Massachusetts Medical Society.
The Journal of Thoracic and Cconsidered even with significantly less exposure to tobacco
smoke. Other environmental exposures and radon exposure
in the home increase risk but are difficult to quantify.
Risk calculators, available on the Internet, are recom-
mended for assistance in evaluation. In an example
provided by the Liverpool Lung Project, an English
77-year-old man, never smoker, but with an early-onset
family history of lung cancer and occupational exposure
to asbestos, has an estimated 5-year risk of developing
lung cancer of 3.17%. The general population risk in En-
gland and Wales for men aged 75 to 79 years is approxi-
mately 2.5%.10 Our threshold to screen for cumulative
risk of 5% or greater over 5 years was in conformity with
the UK Lung Screen trial, which uses the Liverpool Lung
Project to calculate risk.13
A second model using prospective data from the Pros-
tate, Lung, Colorectal and Ovarian Cancer Screening Trial
offers an online nomogram to allow estimation of the
9-year probability of lung cancer given an individual’s spe-
cific risk factors. This model includes age, socioeconomic
status, body mass index, family history of lung cancer,
chronic obstructive pulmonary disease, and smoking dura-
tion.14 We believe these databases can be made available to
all citizens through Internet sources, thus allowing self-
assessment of lung cancer risk. Our guidelines were in-
tended to be flexible enough to guide this potential demand
for screening advice.
Antecedent cancer history increases the probability that
a lung nodule is malignant.15 Furthermore, antecedent can-
cers may reflect complex genetic or environmental factors
that predict cancer development at an earlier age and lower
tobacco exposure. Although this subgroup was ineligible
for participation in previous screening trials, we believe an-
tecedent cancer becomes an indication to start lung cancer
screening at an earlier age and lesser tobacco exposure.ardiovascular Surgery c Volume 144, Number 1 37
Clinical Guidelines Jaklitsch et alRadiation treatment for prior thoracic malignancy may also
increase risk of lung cancer at an earlier age. Radiation risks
are linear with dose, and the risk for radiation-related cancer
typically begins approximately 2 decades after exposure.
Incompletely understood genetic susceptibilities likely
contribute to the development of lung cancer and may
well underlie the variability of development of lung disease
in response to exposure to tobacco smoke. Family history is
disconcerting to patients, particularly when family history
includes multiple cancers and multiple first-degree relatives
who have died from lung cancer (especially those aged<60
years). This risk may be higher in women and African
Americans. In addition, there may be a hereditary suscepti-
bility toward lung cancer that is largely unexplored.
Management of Low-Dose Computed Tomography
Findings
A baseline LDCT scan that shows a solid or part-solid
nodule should follow the algorithm depicted in Figure 3.
A baseline LDCT scan that shows a ground-glass opacity
or nonsolid nodule should follow the algorithm depicted
in Figure 4. A new nodule found on an annual LDCT
scan should be managed on the basis of the probability of
suspected inflammation as depicted in Figure 5. Further ex-
planations of these flowcharts are available in a simulta-
neous publication.16
DISCUSSION
The AATS recommends lung cancer screening for 3 dis-
tinct groups. Level 1 evidence in favor of screening currently
exists for North Americans aged 55 to 79 years with a 30
pack-year smoking history. Furthermore, lung cancer survi-
vors areanextremelyhigh-riskgroup fordevelopinga second
lung cancer and should be screened with LDCT starting 5
years after treatment. Finally, younger patients (aged 50
years) with a 20 pack-year smoking history should be
screened if they have an additional risk factor that produces
a 5% risk of developing a lung cancer over the next 5 years.
The AATS recommends continuing reevaluation of lung
cancer screening presented in this document and will en-
courage the interdisciplinary and intersociety engagements
that will further standardize the understanding and availabil-
ity of LDCT screening for the early detection of lung cancer.
We agree with the IASLC guidance on screening, which
suggests those considering screening should do so in envi-
ronments where multidisciplinary teams are available for
the management of indeterminate and positive screening
scans.2 Furthermore, the provision of care by an interdisci-
plinary team of thoracic surgeonsworkingwith radiologists,
pulmonologists, and oncologists is required to ensure de-
creased mortality from lung cancer outside of strict clinical
trials in academic centers and appropriate minimally inva-
sive capabilities. It is most desirable to create a program
for lung cancer screening that also supports smoking38 The Journal of Thoracic and Cardiovascular Surgecessation and collection of data that will allow study of out-
comes that are important for the practice of evidence-based
medicine in the era of personalized health care.CONCLUSIONS
Within the 75-year lifespan of the American Association
of Thoracic Surgery, lung cancer has become an epidemic,
and initial clinical trials to use screening CXR or sputum cy-
tology were unsuccessful in reducing lung cancer–specific
mortality. Now a useful screening method in LDCT has
been proven to increase the survival of those with this dis-
ease. The future will bring refinements in screening and
one day may make a blood, urine, or breath test available.
However, at this time and for the first time in medical his-
tory, we can say, ‘‘lung cancer screening—the time has
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